Synergistic Integration of Alpha-1 Antitrypsin with AI, IoT, and Blockchain for Enhanced GVHD Risk Management

The present inventive concept discloses novel systems and methods for reducing the risk of acute graft versus host disease (GVHD) in hematopoietic cell transplantation recipients by integrating alpha-1 antitrypsin administration with cutting-edge technologies like artificial intelligence, Internet of Things, and blockchain.

The original patent disclosed methods for reducing GVHD risk by administering alpha-1 antitrypsin according to specific schedules. However, these methods lacked the ability to personalize treatment regimens, track patient data in real-time, and leverage advanced analytics for predictive risk assessment. The present inventive concept addresses these limitations by synergistically combining alpha-1 antitrypsin administration with AI, IoT, and blockchain technologies.

The inventive concept comprises a blockchain-based patient data management platform that integrates alpha-1 antitrypsin administration data with machine learning-based predictive analytics for personalized GVHD risk assessment. Additionally, IoT-enabled wearable devices collect patient data, which is analyzed using machine learning algorithms to identify high-risk patients. The system also includes a computer-implemented optimization module that identifies optimal dosing regimens based on patient-specific data, including genetic markers and treatment outcomes. Furthermore, the system enables real-time monitoring and adjustment of alpha-1 antitrypsin administration schedules using IoT-enabled sensors and cloud-based servers.

The present inventive concept is novel and non-obvious in that it combines alpha-1 antitrypsin administration with AI, IoT, and blockchain technologies to create a personalized, real-time, and data-driven approach to GVHD risk management. The integration of these technologies enables a level of precision and adaptability that was not possible with the original patent's methods.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT devices, or blockchain platforms. Additionally, the system could be adapted for use in other medical contexts, such as solid organ transplantation or autoimmune disease treatment.

The present inventive concept has significant commercial potential in the field of hematopoietic cell transplantation, with potential applications in personalized medicine, precision health, and digital therapeutics. The target market includes pharmaceutical companies, biotech firms, and healthcare providers involved in transplantation and immunotherapy.